Bispecific antibodies targeting multiple SARS-CoV-2 sites offer enhanced neutralization against emerging variants, advancing ...

Meloxicam is an enolcarboxamide with preferential COX-2 inhibitory activity. In vitro studies with human tissues have confirmed the high affinity of meloxicam for COX-2, whereas COX-1 was ...

and is less sensitive to NSAIDs than COX-2 induced by lipopolysaccharide in murine macrophages, although it is recognized by the same antibody. Similarly, given the differences in expression and ...

The virus that causes COVID-19 has been very good at mutating to keep infecting people—so good that most antibody treatments developed during the pandemic are no longer effective. Now a team led by ...